Can vaginal lactobacillus suppositories help reduce urinary tract infections?
Lactobacillus
Recurrent urinary tract infections
Vaginal health
Vaginal probiotic
Vaginal supplement
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
02
02
2023
accepted:
21
04
2023
medline:
28
11
2023
pubmed:
1
7
2023
entrez:
1
7
2023
Statut:
ppublish
Résumé
Recurrent urinary tract infections (rUTIs) are a burden to patients and the health care economy. Vaginal probiotics and supplements have gained significant attention in mainstream media and lay press as a non-antibiotic alternative. We performed a systematic review to determine whether vaginal probiotics are an effective means of prophylaxis for rUTI. A PubMed/MEDLINE article search was performed from inception to August 2022 for prospective, in vivo use of vaginal suppositories for the prevention of rUTIs. Search terms included: vaginal probiotic suppository (34 results), vaginal probiotic randomized (184 results), vaginal probiotic prevention (441 results), vaginal probiotic UTI (21 results), and vaginal probiotic urinary tract infection (91 results). A total of 771 article titles and abstracts were screened. A total of 8 articles fit the inclusion criteria and were reviewed and summarized. Four were randomized controlled trials, with 3 of the studies having a placebo arm. Three were prospective cohort studies, and 1 was a single arm, open label trial. Five of the 7 articles that specifically evaluated for rUTI reduction with vaginal suppositories did find a decreased incidence with probiotic use; however, only 2 had statistically significant results. Both of these were studies of Lactobacillus crispatus and were not randomized. Three studies demonstrated the efficacy and safety of Lactobacillus as a vaginal suppository. Current data support the use of vaginal suppositories containing Lactobacillus as a safe, non-antibiotic measure, but actual reduction of rUTI in susceptible women remains inconclusive. The appropriate dosing and duration of therapy remain unknown.
Identifiants
pubmed: 37392226
doi: 10.1007/s00192-023-05568-4
pii: 10.1007/s00192-023-05568-4
pmc: PMC10682044
doi:
Substances chimiques
Suppositories
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2713-2718Informations de copyright
© 2023. The Author(s).
Références
Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S30-4
pubmed: 16859900
Int J Urol. 2021 Oct;28(10):1026-1031
pubmed: 34258813
Urology. 2019 Jun;128:47-54
pubmed: 30796990
Clin Ther. 1992 Jan-Feb;14(1):11-6
pubmed: 1576619
J Urol. 2021 Sep;206(3):688-695
pubmed: 34233479
Infect Dis Clin North Am. 2014 Mar;28(1):1-13
pubmed: 24484571
Scand J Prim Health Care. 1994 Dec;12(4):239-43
pubmed: 7863140
Clin Infect Dis. 2011 May;52(10):1212-7
pubmed: 21498386
BJOG. 2020 Jan;127(2):287-299
pubmed: 31299136
Pharmacol Res Perspect. 2021 Oct;9(5):e00787
pubmed: 34609059
J Obstet Gynaecol. 2018 Jul;38(5):693-696
pubmed: 29526145
Res Microbiol. 2017 Nov - Dec;168(9-10):782-792
pubmed: 28435139
Dis Mon. 2003 Feb;49(2):53-70
pubmed: 12601337
Infect Dis Obstet Gynecol. 2007;2007:35387
pubmed: 18288237
PLoS One. 2014 Aug 22;9(8):e105998
pubmed: 25148517
FEMS Immunol Med Microbiol. 1993 Apr;6(4):251-64
pubmed: 8499891
Sci Rep. 2022 Feb 17;12(1):2698
pubmed: 35177690
Arch Gynecol Obstet. 2014 Mar;289(3):479-89
pubmed: 24170161
Can J Microbiol. 1988 Mar;34(3):339-43
pubmed: 3138016
Anaerobe. 2011 Dec;17(6):410-3
pubmed: 21549209
Br J Gen Pract. 2022 Mar 31;72(717):e252-e260
pubmed: 35314431